How does one approach maintenance treatment in transplant in-eligible patients with newly diagnosed multiple myeloma?  

IMROZ and BENEFIT trials are interesting in that they are billed as for transplant-ineligible patients, yet frail patients were excluded, so I don't think they give us the answer for how to maintain a frail patient. The best answer for a frail patient is, I believe, the MAIA trial, which gives DRD t...

Data from these two trials do not change practice from a maintenance standpoint. The regimen should be decided based on patient frailty and risk status, leaning towards 2 drugs for high risk and one for standard risk, frailty being the limiting factor for those with high risk where one drug may have...